Rottner, Antje K. http://orcid.org/0000-0002-7736-510X
Ye, Yingying http://orcid.org/0000-0003-3648-7167
Navarro-Guerrero, Elena
Rajesh, Varsha
Pollner, Alina
Bevacqua, Romina J.
Yang, Jing http://orcid.org/0000-0001-5975-4315
Spigelman, Aliya F.
Baronio, Roberta
Bautista, Austin
Thomsen, Soren K.
Lyon, James
Nawaz, Sameena
Smith, Nancy
Wesolowska-Andersen, Agata
Fox, Jocelyn E. Manning
Sun, Han http://orcid.org/0000-0002-3390-0027
Kim, Seung K. http://orcid.org/0000-0001-6135-7810
Ebner, Daniel
MacDonald, Patrick E.
Gloyn, Anna L. http://orcid.org/0000-0003-1205-1844
Funding for this research was provided by:
Wellcome Trust (200837)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (DK085545, DK126185)
Article History
Received: 21 May 2021
Accepted: 26 October 2022
First Online: 21 December 2022
Competing interests
: The authors declare the following competing interests: A.K.R. is now an employee of AstraZeneca, S.K.T. is now an employee of Vertex Pharmaceuticals and A.W-A. is now an employee of Genomics plc. D.E. and E.N-G are now also affiliated with XCellomics. All experimental work by A.K.R., S.K.T. and A.W-A. was carried out under employment at the University of Oxford. A.K.R. holds stocks in Astra Zeneca. A.L.G.’s spouse holds stock options in Roche. The other authors declare no competing interests.